# Galym Imanbayev

> Galym Imanbayev is a Series B investor at Lightspeed Venture Partners backing Medical. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners)
- Location: Menlo Park, United States
- Total investments: 17
- Last investment: Jun 2026
- Lead investor: 65%
- Last updated: Aug 2026
- Website: https://lsvp.com/team/galym-imanbayev
- Facebook: https://www.facebook.com/galym.imanbayev

Galym Imanbayev is a Series B investor at Lightspeed Venture Partners in Menlo Park focused on Medical and Health Care. Galym Imanbayev joined Lightspeed as a Partner focused on the Health sector in 2020.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 7 | 41% |
| Health Care | 7 | 41% |
| Artificial Intelligence | 4 | 24% |
| Biotechnology | 3 | 18% |
| Software | 2 | 12% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 29% |
| Seed | 4 | 24% |
| Series C | 4 | 24% |
| Series A | 2 | 12% |
| Series D | 1 | 6% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Assort Health | Assort Health is building healthcare that remembers.From call center automation and form intake to referrals, document processing, outreach, and payments, we manage the entire patient journey for providers. Our platform is the most widely used AI agents platform for the patient journey, built on 180 million specialty patient interactions and amodel that handles the complexity general-purpose AI can’t.Healthcare organizations see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score.With over $222M raised from Menlo Ventures, Lightspeed, First Round Capital, Apolo Ohno, and Joe Montana, Assort is becoming the standard for how providers use AI to transform the patient journey.Learn more at assorthealth.com | $120M | Series C | Jun 24, 2026 |  |
| Assort Health | Assort Health is building healthcare that remembers.From call center automation and form intake to referrals, document processing, outreach, and payments, we manage the entire patient journey for providers. Our platform is the most widely used AI agents platform for the patient journey, built on 180 million specialty patient interactions and amodel that handles the complexity general-purpose AI can’t.Healthcare organizations see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score.With over $222M raised from Menlo Ventures, Lightspeed, First Round Capital, Apolo Ohno, and Joe Montana, Assort is becoming the standard for how providers use AI to transform the patient journey.Learn more at assorthealth.com | $76M | Series B | Oct 02, 2025 |  |
| Frontera Health | Frontera Health is changing autism care in underprivileged regions with AI-powered tools that assist physicians in evaluating and treating children with autism and related diseases. | $32M | Seed | Feb 18, 2025 |  |
| Abridge | Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | $250M | Series D | Feb 17, 2025 |  |
| Evermore | Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America. | $54.2M | Series B | Dec 03, 2024 |  |
| Tennr | Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports. | $37M | Series B | Oct 22, 2024 |  |
| Abridge | Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | $150M | Series C | Feb 23, 2024 |  |
| Aledade | Aledade is a primary care physician platform to provide everything the doctors to create and run an Accountable Care Organization. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) from business and practice transformation services to upfrontcapital and a cutting-edge technology platform. The company's customized solutions and continuous on-the-ground support of our physician partners will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.Adelade was founded in 2014 and is headquartered in Bethesda, Maryland, United States. | $260M | Series F | Jun 21, 2023 |  |
| Zag Bio | Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. |  | Seed | Jan 01, 2023 |  |
| Fathom | Fathom develops a coding automation platform that uses artificial intelligence to automatically review incoming charts and offers full-service coding services and comprehensive real-time audits, enabling medical operators to automate their coding and optimize their business. | $46M | Series B | Nov 09, 2022 |  |

10 of 17 investments shown.

## Co-investors
- [IVP](https://shizune.co/investors/profile/institutional-venture-partners) — VC Fund, 9 deals together
- [Silverton Partners](https://shizune.co/investors/profile/silverton-partners) — VC Fund, 4 deals together
- [Define Ventures](https://shizune.co/investors/profile/define-ventures) — VC Fund, 3 deals together
- [Menlo Ventures](https://shizune.co/investors/profile/menlo-ventures) — VC Fund, 3 deals together
- [Qiming Venture Partners USA](https://shizune.co/investors/profile/qiming-venture-partners-usa) — VC Fund, 3 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 2 deals together

## About Lightspeed Venture Partners

VC Fund · Menlo Park, United States

Lightspeed Venture Partners is a venture capital firm that engages in consumer, enterprise, technology, and cleantech markets. It focuses on seed, early-stage, later-stage, expansion-stage, start-ups, growth companies, and incubation, and specializes in debt financing for start-ups and growth companies.Lightspeed Venture Partners invests invarious sectors that include enterprise, consumer, big data, bitcoin, enterprise technology, cleantech, mobile, internet, financial technology, cloud solutions, e-commerce, storage, media, networking, energy, and software, software-as-a-service, information technology, biotechnology, and social.

5 contacts available at Lightspeed Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Arsham Memarzadeh | Partner | https://shizune.co/investors/profile/arsham-memarzadeh |
| Galym Imanbayev | Partner | https://shizune.co/investors/profile/galym-imanbayev-3ecc |
| James Ephrati | Partner | https://shizune.co/investors/profile/james-ephrati |
| Justin Overdorff | Partner | https://shizune.co/investors/profile/justin-overdorff |
| Michael Mignano | Partner | https://shizune.co/investors/profile/michael-mignano |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Galym Imanbayev invest in?

Galym Imanbayev invests primarily in Medical, Health Care and Artificial Intelligence startups, most often at Series B and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Galym Imanbayev last invest?

The most recent investment recorded for Galym Imanbayev closed in Jun 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co